These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28784436)

  • 1. Value of the sodium-channel blocker challenge in Brugada syndrome.
    Therasse D; Sacher F; Babuty D; Mabo P; Mansourati J; Kyndt F; Redon R; Schott JJ; Barc J; Probst V; Gourraud JB
    Int J Cardiol; 2017 Oct; 245():178-180. PubMed ID: 28784436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
    Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C
    Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity.
    Therasse D; Sacher F; Petit B; Babuty D; Mabo P; Martins R; Jesel L; Maury P; Pasquie JL; Mansourati J; Dupuis JM; Kyndt F; Thollet A; Guyomarch B; Barc J; Schott JJ; Le Marec H; Redon R; Probst V; Gourraud JB
    Heart Rhythm; 2017 Oct; 14(10):1442-1448. PubMed ID: 28666944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia.
    Hasdemir C; Payzin S; Kocabas U; Sahin H; Yildirim N; Alp A; Aydin M; Pfeiffer R; Burashnikov E; Wu Y; Antzelevitch C
    Heart Rhythm; 2015 Jul; 12(7):1584-94. PubMed ID: 25998140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation.
    Pambrun T; Mercier A; Chatelier A; Patri S; Schott JJ; Le Scouarnec S; Chahine M; Degand B; Bois P
    Heart Rhythm; 2014 Aug; 11(8):1393-400. PubMed ID: 24768612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yield and Pitfalls of Ajmaline Testing in the Evaluation of Unexplained Cardiac Arrest and Sudden Unexplained Death: Single-Center Experience With 482 Families.
    Tadros R; Nannenberg EA; Lieve KV; Škorić-Milosavljević D; Lahrouchi N; Lekanne Deprez RH; Vendrik J; Reckman YJ; Postema PG; Amin AS; Bezzina CR; Wilde AAM; Tan HL
    JACC Clin Electrophysiol; 2017 Dec; 3(12):1400-1408. PubMed ID: 29759671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.
    Maury P; Audoubert M; Cintas P; Rollin A; Duparc A; Mondoly P; Chiriac AM; Acket B; Zhao X; Pasquié JL; Cardin C; Delay M; Sadron M; Carrié D; Galinier M; Davy JM; Arne-Bès MC; Raczka F
    Heart Rhythm; 2014 Oct; 11(10):1721-7. PubMed ID: 25016148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual phenotypic transmission in Brugada syndrome.
    Hermida JS; Arnalsteen-Dassonvalle E; Kubala M; Mathiron A; Traulle S; Anbazhagan K; Hermida A; Rochette J
    Arch Cardiovasc Dis; 2013; 106(6-7):366-72. PubMed ID: 23810369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome.
    Dobbels B; De Cleen D; Ector J
    Europace; 2016 Oct; 18(10):1501-1506. PubMed ID: 26941343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations.
    Hong K; Brugada J; Oliva A; Berruezo-Sanchez A; Potenza D; Pollevick GD; Guerchicoff A; Matsuo K; Burashnikov E; Dumaine R; Towbin JA; Nesterenko V; Brugada P; Antzelevitch C; Brugada R
    Circulation; 2004 Nov; 110(19):3023-7. PubMed ID: 15520322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should all individuals with a nondiagnostic Brugada-electrocardiogram undergo sodium-channel blocker test?
    Zorzi A; Migliore F; Marras E; Marinelli A; Baritussio A; Allocca G; Leoni L; Perazzolo Marra M; Basso C; Buja G; Thiene G; Iliceto S; Delise P; Corrado D
    Heart Rhythm; 2012 Jun; 9(6):909-16. PubMed ID: 22334153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant response to ajmaline challenge in SCN5A mutation carriers: experience from a large familial study.
    Gandjbakhch E; Fressart V; Duthoit G; Marquié C; Deharo JC; Pousset F; Hebert JL; Simon F; Himbert C; Klug D; Charron P; Hidden-Lucet F
    Int J Cardiol; 2014 Mar; 172(1):256-8. PubMed ID: 24476701
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective evaluation of the familial prevalence of the brugada syndrome.
    Hermida JS; Dassonvalle E; Six I; Amant C; Coviaux F; Clerc J; Herent D; Hermida A; Rochette J; Jarry G
    Am J Cardiol; 2010 Dec; 106(12):1758-62. PubMed ID: 21126620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers.
    Amin AS; Reckman YJ; Arbelo E; Spanjaart AM; Postema PG; Tadros R; Tanck MW; Van den Berg MP; Wilde AAM; Tan HL
    Int J Cardiol; 2018 Sep; 266():128-132. PubMed ID: 29709244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and electrocardiographic predictors of positive response to the intravenous sodium channel blockers in patients suspected of the Brugada syndrome.
    Shahrzad S; Khoramshahi M; Aslani A; Fazelifar AF; Haghjoo M
    Int J Cardiol; 2013 May; 165(2):285-90. PubMed ID: 21917337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores.
    Tadros R; Tan HL; ; El Mathari S; Kors JA; Postema PG; Lahrouchi N; Beekman L; Radivojkov-Blagojevic M; Amin AS; Meitinger T; Tanck MW; Wilde AA; Bezzina CR
    Eur Heart J; 2019 Oct; 40(37):3097-3107. PubMed ID: 31504448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brugada syndrome: clinical presentation and genotype-correlation with magnetic resonance imaging parameters.
    Rudic B; Schimpf R; Veltmann C; Doesch C; Tülümen E; Schoenberg SO; Borggrefe M; Papavassiliu T
    Europace; 2016 Sep; 18(9):1411-9. PubMed ID: 26511399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Peak to T-End Interval for Prediction of Positive Response to Ajmaline Challenge Test in Suspected Brugada Syndrome Patients.
    Thapanasuta M; Chokesuwattanaskul R; Leelapatana P; Rungpradubvong V; Prechawat S
    Med Sci (Basel); 2022 Dec; 10(4):. PubMed ID: 36548004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy.
    Papadakis M; Papatheodorou E; Mellor G; Raju H; Bastiaenen R; Wijeyeratne Y; Wasim S; Ensam B; Finocchiaro G; Gray B; Malhotra A; D'Silva A; Edwards N; Cole D; Attard V; Batchvarov VN; Tome-Esteban M; Homfray T; Sheppard MN; Sharma S; Behr ER
    J Am Coll Cardiol; 2018 Mar; 71(11):1204-1214. PubMed ID: 29544603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex Brugada syndrome inheritance in a family harbouring compound SCN5A and CACNA1C mutations.
    Béziau DM; Barc J; O'Hara T; Le Gloan L; Amarouch MY; Solnon A; Pavin D; Lecointe S; Bouillet P; Gourraud JB; Guicheney P; Denjoy I; Redon R; Mabo P; le Marec H; Loussouarn G; Kyndt F; Schott JJ; Probst V; Baró I
    Basic Res Cardiol; 2014; 109(6):446. PubMed ID: 25341504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.